{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:12Z","timestamp":1790352192551,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity poses a\u00a0clear challenge to the cardiovascular landscape.\u00a0In this viewpoint, we advocate that we\u00a0need to prepare for the practical implementation of weight management in Dutch cardiology practice\u00a0by 1)\u00a0educating ourselves and our peers on obesity and its treatment thereof, 2)\u00a0considering how to facilitate the appropriate amount of clinical follow-up, and 3)\u00a0establish local arrangements with all health care professionals involved in the chain of lifelong atherosclerotic cardiovascular disease\u00a0risk management.\u00a0Pending the results of ongoing clinical trials involving weight management therapies tested for other cardiovascular conditions (e.g. heart failure and atrial fibrillation), and the evolving landscape of health care budgets and capacity, it is to be expected that the role of weight management therapies will become increasingly prominent in cardiology practice: we therefore argue it would be wise to make an early start with systematic implementation.<\/jats:p>","DOI":"10.1007\/s12471-026-02075-1","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:32:05Z","timestamp":1790058725000},"page":"380-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Weight management in cardiology practice: challenges and opportunities"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-4839","authenticated-orcid":false,"given":"Maarten J. G.","family":"Leening","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice M. A. C.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E. W.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"21","key":"2075_CR1","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley\u00a0TM, Poirier\u00a0P, Burke\u00a0LE, et\u00a0al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984\u2013e1010.","journal-title":"Circulation"},{"issue":"17","key":"2075_CR2","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","volume":"29","author":"F Lopez-Jimenez","year":"2021","unstructured":"Lopez-Jimenez\u00a0F, Almahmeed\u00a0W, Bays\u00a0H, et\u00a0al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2021;29(17):2218\u201337.","journal-title":"Eur J Prev Cardiol"},{"issue":"38","key":"2075_CR3","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","volume":"45","author":"KC Koskinas","year":"2024","unstructured":"Koskinas\u00a0KC, Van Craenenbroecket\u00a0EM, Antoniades\u00a0C, et\u00a0al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024;45(38):4063\u201398.","journal-title":"Eur Heart J"},{"issue":"1","key":"2075_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra1112570","volume":"366","author":"EG Nabel","year":"2012","unstructured":"Nabel\u00a0EG, Braunwald\u00a0E. A\u00a0tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366(1):54\u201363.","journal-title":"N Engl J Med"},{"issue":"13","key":"2075_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1056\/NEJMc1201171","volume":"366","author":"BY Laing","year":"2012","unstructured":"Laing\u00a0BY, Katz\u00a0MH, Tarone\u00a0RE, et\u00a0al. Coronary arteries, myocardial infarction, and history. N Engl J Med. 2012;366(13):1258\u201360.","journal-title":"N Engl J Med"},{"key":"2075_CR6","doi-asserted-by":"publisher","unstructured":"Wood DA, Jennings CS, Kotseva K, et al. ESC Guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey. Eur Heart J. 2026; ehag741. https:\/\/doi.org\/10.1093\/eurheartj\/ehag741.","DOI":"10.1093\/eurheartj\/ehag741"},{"key":"2075_CR7","volume":"165","author":"LM de Brauw","year":"2021","unstructured":"de Brauw\u00a0LM. De gecombineerde leefstijlinterventie: een papieren tijger in de strijd tegen obesitas? Ned Tijdschr Geneeskd. 2021;165:D5885.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2075_CR8","doi-asserted-by":"publisher","DOI":"10.21945\/RIVM-2025-0085","author":"M Oosterhoff","year":"2025","unstructured":"Oosterhoff\u00a0M, Rotteveel\u00a0A, Hulshof\u00a0TA, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), et\u00a0al. Deelname en uitval bij de gecombineerde leefstijlinterventie (GLI): wie en waarom? rapport 2025-0085. 2025; https:\/\/doi.org\/10.21945\/RIVM-2025-0085.","journal-title":"rapport 2025-0085"},{"issue":"20","key":"2075_CR9","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","volume":"43","author":"SL van Veldhuisen","year":"2022","unstructured":"van Veldhuisen\u00a0SL, Gorter\u00a0TM, van Woerden\u00a0G, et\u00a0al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955\u201369.","journal-title":"Eur Heart J"},{"issue":"10531","key":"2075_CR10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck\u00a0MA, Tuttle\u00a0KR, Tsch\u00f6p\u00a0MH, Bl\u00fcher\u00a0M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892\u2013908.","journal-title":"Lancet"},{"issue":"5","key":"2075_CR11","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee\u00a0MMY, Sattar\u00a0N, Pop-Busui\u00a0R, et\u00a0al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025;48(5):846\u201359.","journal-title":"Diabetes Care"},{"issue":"7-8","key":"2075_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12471-025-01967-y","volume":"33","author":"FMAC Martens","year":"2025","unstructured":"Martens\u00a0FMAC, Visseren\u00a0FLJ, Westerink\u00a0J, et\u00a0al. 2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: statement of endorsement by the NVVC. Neth Heart J. 2025;33(7-8):216\u201325.","journal-title":"Neth Heart J"},{"issue":"24","key":"2075_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, Brown-Frandsen\u00a0K, Colhoun\u00a0KM, et\u00a0al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"2075_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","volume":"85","author":"JY Chen","year":"2025","unstructured":"Chen\u00a0JY, Hsu\u00a0TW, Liu\u00a0JH, et\u00a0al. Kidney and cardiovascular outcomes among patients with CKD receiving GLP\u20111 receptor agonists: a\u00a0systematic review and meta-analysis of randomized trials. Am J Kidney Dis. 2025;85(5):555\u201369.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2075_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba\u00a0R, Hartman\u00a0ML, Lawitz\u00a0EJ, et\u00a0al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"21","key":"2075_CR16","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal\u00a0AJ, Newsome\u00a0PN, Kliers\u00a0I, et\u00a0al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"13","key":"2075_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra\u00a0A, Grunstein\u00a0RR, Fietze\u00a0I, et\u00a0al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"17","key":"2075_CR18","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal\u00a0H, Bays\u00a0H, Czernichow\u00a0S, et\u00a0al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573\u201383.","journal-title":"N Engl J Med"},{"issue":"12","key":"2075_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, Abildstr\u00f8m\u00a0SZ, Borlaug\u00a0BA, et\u00a0al. Semaglutide in patients with obesity-related heart failure and preserved ejection fraction. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"5","key":"2075_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer\u00a0M, Zile\u00a0MR, Kramer\u00a0CM, et\u00a0al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"2075_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2023.12.029","volume":"83","author":"MK Hansen","year":"2024","unstructured":"Hansen\u00a0MK, Olesen\u00a0KKW, Gyldenkerne\u00a0C, et\u00a0al. Eligibility for and preventive potential of semaglutide in overweight and obese patients with myocardial infarction. J\u00a0Am Coll Cardiol. 2024;83(9):956\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2075_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamacardio.2024.4657","volume":"10","author":"I Shi","year":"2025","unstructured":"Shi\u00a0I, Khan\u00a0SS, Yeh\u00a0RW, et\u00a0al. Semaglutide eligibility across all current indications for US adults. JAMA Cardiol. 2025;10(1):96\u20138.","journal-title":"JAMA Cardiol"},{"key":"2075_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103992","volume":"96","author":"A Moiz","year":"2026","unstructured":"Moiz\u00a0A, Filion\u00a0KB, Kn\u00e4uper\u00a0B, et\u00a0al. Weight maintenance after discontinuation of GLP\u20111 therapies. eClinicalMedicine. 2026;96:103992.","journal-title":"eClinicalMedicine"},{"issue":"8","key":"2075_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding\u00a0JPH, Batterham\u00a0RL, Davies\u00a0M, et\u00a0al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"10545","key":"2075_CR25","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/S0140-6736(26)00656-2","volume":"407","author":"DB Horn","year":"2026","unstructured":"Horn\u00a0DB, Aronne\u00a0LJ, Wharton\u00a0S, et\u00a0al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305\u201318.","journal-title":"Lancet"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02075-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-026-02075-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02075-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:08:37Z","timestamp":1790348917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-026-02075-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2075"],"URL":"https:\/\/doi.org\/10.1007\/s12471-026-02075-1","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr M.J.G.\u00a0Leening reports receiving support for investigator initiated research from Amgen; AstraZeneca; Eli Lilly; Novartis; Novo Nordisk; Sanofi; educational grants from Amarin; and Amgen; speaker fees from Amgen; Daiichi Sankyo; Merck Sharpe & Dohme; Novartis; Novo Nordisk, and Sanofi; served on advisory boards for AstraZeneca; Daiichi Sankyo; Merck Sharpe & Dohme; Novartis; and Sanofi; serves on a\u00a0steering committee and\/or as a\u00a0local investigator for trials coordinated by Amgen; AstraZeneca; Daiichi Sankyo; Novartis; and Sanofi. Dr F.M.A.C.\u00a0Martens reports receiving unrestricted support to Amsterdam UMC for investigator initiated research from Amarin; Novartis; and Novo Nordisk. Dr M.E.W.\u00a0Hemels reports speaker fees from AstraZeneca; Bristol-Myers Squibb-Pfizer Alliance; Boehringer Ingelheim; Daiichi Sankyo; Novartis; Novo Nordisk; and Roche diagnostics. Drs M.J.G.\u00a0Leening and F.M.A.C.\u00a0Martens are members of the working group on medication (WG Geneesmiddelen); working group on cardiovascular prevention and cardiac rehabilitation (WG CPH); and Dutch multidisciplinary cardiovascular risk management guidelines committee, on behalf of the of the Netherlands Society of Cardiology (NVvC).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}